iShares MSCI Israel ETF (EIS) is a publicly traded the market company. As of May 21, 2026, EIS trades at $130.00 with a market cap of $0 and a P/E ratio of 0.00. EIS moved -2.70% today. Year to date, EIS is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $0.00 to $0.00. Rallies surfaces EIS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
iShares MSCI Israel ETF Buoyed by Teva’s 58% Remission Rates and Target Raises: Teva Pharmaceutical, a 9.59% holding in iShares MSCI Israel ETF, reported 58% and 47% ulcerative colitis remissions and 55% and 41% Crohn’s endoscopic responses in a 44-week RELIEVE UCCD extension study. Shares rose 2.85% as analysts lifted targets to $45, $38 and $40, boosting ETF outlook.
| Metric | Value |
|---|---|
| Price | $130.00 |
| Market Cap | $0 |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $0.00 |
| 52-Week Low | $0.00 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
EIS analyst coverage data. Average price target: $0.00.